Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation

This phase II trial studies how well contrast-enhanced ultrasound (CEUS) works for diagnosing patients with renal cell cancer (RCC) that has come back (recurrent) after an ablation. Diagnostic imaging, such as CEUS, may help find and monitor long term renal cell cancer recurrence following cryo or microwave ablation.

Inclusion Criteria:Previously received cryotherapy or microwave therapy of RCCHas available contrast enhanced (CE)-MRI or CE-CT imaging prior to ablative therapyHave previously had or are scheduled to have a contrast-enhanced MRI/CT for the monitoring of RCC recurrence within 2 weeks of the CEUS studyBe at least 18 years of ageBe medically stableIf a female of child-bearing age, must have a negative pregnancy testHave signed Informed Consent to participate in the studyExclusion Criteria:Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictablePatients with known sensitivities to the components of LumasonPatients with severe emphysema, pulmonary vasculitis, or a history of pulmonary emboli